SUBFOVEAL CHOROIDAL THICKNESS IN PAPILLITIS TYPE OF VOGT-KOYANAGI-HARADA DISEASE AND IDIOPATHIC OPTIC NEURITIS.
OBJECTIVE
To evaluate the subfoveal choroidal thickness before and after treatment in papillitis type of Vogt-Koyanagi-Harada (VKH) disease and idiopathic optic neuritis (ON) using enhanced depth imaging spectral domain optical coherence tomography.


METHODS
A total of 11 eyes of 7 patients (average age 47.3 years old) with papillitis type of VKH disease and 11 eyes of 8 patients (average 36.4 years old) with idiopathic ON case were included. The subfoveal choroidal thickness before and 1 month after treatment was measured using enhanced depth imaging spectral domain optical coherence tomography technique. Diagnosis was defined using fluorescein and indocyanine green angiography for VKH disease and magnetic resonance imaging for ON. Either case was treated with systemic steroid therapy.


RESULTS
The mean subfoveal choroidal thickness before treatment in papillitis type of VKH disease was significantly thicker than in idiopathic ON case (527 ± 119 μm vs. 321 ± 86 μm, P < 0.01). Choroidal thickness in papillitis type of VKH disease decreased significantly to 313 ± 91 μm 1 month after treatment (P < 0.01, as compared with baseline), whereas choroidal thickness in idiopathic ON case remained about the same (319 ± 89 μm, P = 0.62, as compared with baseline).


CONCLUSIONS
Although papillitis type of VKH disease is often misdiagnosed as idiopathic ON case, the initial choroidal thickness and its change after treatment may be useful in the differential diagnosis and management.
*Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan; and †Department of Ophthalmology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Ichiro
I
Maruko
Tomohiro
T
Iida
Yukinori
Y
Sugano
Sae
S
Go
Tetsuju
T
Sekiryu
D000293:Adolescent; D000328:Adult; D000368:Aged; D002829:Choroid / Q000473:pathology*; D003937:Diagnosis, Differential; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009902:Optic Neuritis / Q000175:diagnosis* / Q000188:drug therapy; D009929:Organ Size; D010211:Papilledema / Q000175:diagnosis* / Q000188:drug therapy; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014607:Uveomeningoencephalitic Syndrome / Q000175:diagnosis* / Q000188:drug therapy; D014792:Visual Acuity
D005938:Glucocorticoids